Diprivan Injection, Emulsion
NDC Package 63323-269-77

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Diprivan (propofol) injection is dIPRIVAN is an intravenous general anesthetic and sedation drug indicated for:•Induction of General Anesthesia for Patients Greater than or Equal to 3 Years of Age•Maintenance of General Anesthesia for Patients Greater than or Equal to 2 Months of Age•Initiation and Maintenance of Monitored Anesthesia Care (MAC) Sedation in Adult Patients•Sedation for Adult Patients in Combination with Regional Anesthesia•Intensive Care Unit (ICU) Sedation of Intubated, Mechanically Ventilated Adult PatientsLimitations of UseDIPRIVAN is not recommended for induction of anesthesia below the age of 3 years or for maintenance of anesthesia below the age of 2 months because its safety and effectiveness have not been established in those populations [see Pediatric Use (8.4)].Safety, effectiveness and dosing guidelines for DIPRIVAN have not been established for MAC sedation in the pediatric population; therefore, it is not recommended for this use [see Pediatric Use (8.4)].DIPRIVAN is not indicated for use in Pediatric ICU sedation since the safety of this regimen has not been established [see Pediatric Use (8.4)]. This formulation utilizes a injection, emulsion delivery system. Marketed by Fresenius Kabi Usa, Llc, this product is identified by NDC 63323-269 and is authorized under FDA application NDA019627.

Identification & Billing

NDC Package Code
63323-269-77
Package Description
20 VIAL in 1 BOX / 50 mL in 1 VIAL (63323-269-75)
Product Code
11-Digit Billing Format
63323026977
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Diprivan
Non-Proprietary Name
Propofol
Substance Name
Propofol
Dosage Form
Injection, Emulsion - An emulsion consisting of a sterile, pyrogen-free preparation intended to be administered parenterally.
Administration Route
  • Intravenous - Administration within or into a vein or veins.
  • Intravenous - Administration within or into a vein or veins.
  • Intravenous - Administration within or into a vein or veins.
  • Intravenous - Administration within or into a vein or veins.
Usage Information
DIPRIVAN is an intravenous general anesthetic and sedation drug indicated for:•Induction of General Anesthesia for Patients Greater than or Equal to 3 Years of Age•Maintenance of General Anesthesia for Patients Greater than or Equal to 2 Months of Age•Initiation and Maintenance of Monitored Anesthesia Care (MAC) Sedation in Adult Patients•Sedation for Adult Patients in Combination with Regional Anesthesia•Intensive Care Unit (ICU) Sedation of Intubated, Mechanically Ventilated Adult PatientsLimitations of UseDIPRIVAN is not recommended for induction of anesthesia below the age of 3 years or for maintenance of anesthesia below the age of 2 months because its safety and effectiveness have not been established in those populations [see Pediatric Use (8.4)].Safety, effectiveness and dosing guidelines for DIPRIVAN have not been established for MAC sedation in the pediatric population; therefore, it is not recommended for this use [see Pediatric Use (8.4)].DIPRIVAN is not indicated for use in Pediatric ICU sedation since the safety of this regimen has not been established [see Pediatric Use (8.4)].

Regulatory & Marketing

Labeler Name
Fresenius Kabi Usa, Llc
Product Type
Human Prescription Drug
FDA Application #
NDA019627
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
11-17-2009
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (63323-269). Click a package code to view its specific billing and regulatory data.

10 VIAL in 1 BOX / 10 mL in 1 VIAL (63323-269-01)
10 VIAL in 1 BOX / 10 mL in 1 VIAL (63323-269-06)
10 VIAL in 1 BOX / 20 mL in 1 VIAL (63323-269-22)
10 VIAL in 1 BOX / 20 mL in 1 VIAL (63323-269-25)
20 VIAL in 1 BOX / 50 mL in 1 VIAL (63323-269-30)
20 VIAL in 1 BOX / 50 mL in 1 VIAL (63323-269-23)
20 VIAL in 1 BOX / 50 mL in 1 VIAL (63323-269-45)
10 VIAL in 1 BOX / 100 mL in 1 VIAL (63323-269-35)
10 VIAL in 1 BOX / 100 mL in 1 VIAL (63323-269-21)
10 VIAL in 1 BOX / 100 mL in 1 VIAL (63323-269-41)
10 VIAL in 1 BOX / 20 mL in 1 VIAL (63323-269-33)
10 VIAL in 1 BOX / 100 mL in 1 VIAL (63323-269-31)
10 VIAL in 1 BOX / 20 mL in 1 VIAL (63323-269-43)

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 63323-269-77 identifies a specific commercial package of 20 vial in 1 box / 50 ml in 1 vial (63323-269-75) of Diprivan, a human prescription drug labeled by Fresenius Kabi Usa, Llc. This injection, emulsion is formulated for intravenous use and contains propofol as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Fresenius Kabi Usa, Llc on November 17, 2009. The current certification is valid through December 31, 2026.

How is this Fresenius Kabi Usa, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 63323026977. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
63323-269-77
11-Digit CMS (5-4-2)
63323-0269-77

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.